SMLR · As filed with the SEC
Semler Scientific income statement, by fiscal year
The statement as Semler Scientific presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Statements of Income · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|
| Revenues | 56,294,000 | 68,184,000 |
| Operating expenses: | ||
| Cost of revenues | 4,759,000 | 6,984,000 |
| Engineering and product development | 4,792,000 | 5,773,000 |
| Sales and marketing | 13,078,000 | 18,147,000 |
| General and administrative | 12,732,000 | 14,290,000 |
| Strategic streamlining | — | 734,000 |
| Total operating expenses | 35,361,000 | 45,928,000 |
| Income from operations | 20,933,000 | 22,256,000 |
| Interest and dividend income, net | 1,877,000 | 2,471,000 |
| Impairment of investments | — | (337,000) |
| Change in fair value of notes held for investment | 128,000 | (307,000) |
| Change in fair value of digital assets | 24,933,000 | — |
| Other income | 13,000 | 17,000 |
| Other income, net | 26,951,000 | 1,844,000 |
| Pre-tax income | 47,884,000 | 24,100,000 |
| Income tax provision | 6,985,000 | 3,517,000 |
| Net income | 40,899,000 | 20,583,000 |
| Net income per share, basic | 5.66 | 3.06 |
| Weighted average number of shares used in computing basic net income per share | 7,228,961 | 6,732,806 |
| Net income per share, diluted | 5.13 | 2.63 |
| Weighted average number of shares used in computing diluted net income per share | 7,980,118 | 7,819,159 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.